EGFR and neoplasm: Several examples have been already mentioned in the paper with regards to how tumor profiling at diagnosis can help us define the individuals that will best benefit from a given treatment, with the most prominent likely being the administration of anti-EGFR drugs to KRAS wild-type only patients in bowel cancer (149).